Pefloxacin CAS 70458-92-3 149676-40-4 RB-1589 Pefloxacine Mesylate Dihydrate Pefloxacine Methansulfonate Dihydrate

Place of Origin: Zhejiang,China (Mainland)
CAS: 70458-92-3;149676-40-4
Molecular formula: C17H20FN3O3
Molecular weight: 333.3574
Refractive index: 1.593
Boiling point: 529.1°C at 760 mmHg
Flash point: 273.8°C
Density: 1.32g/cm3
Vapour Pressur: 5.05E-12mmHg at 25°C

inquiry

skype basketAdd to Basket  Edit

Share |

Product Description

Payment & Shipping Terms Supply Capacity
Payment Terms:L/C, T/T, WUProduction Capacity:100Ton/year
Min. Order:50 KilogramPacking:As per request of...
Means of Transport:Ocean, Air, LandDelivery Date:within 7 days

Pefloxacin (CA:S 70458-92-3; 149676-40-4)


SynonymsRB-1589; Pefloxacine Mesylate Dihydrate; Pefloxacine Methansulfonate Dihydrate
Molecular FormulaC17H20FN3O3
Molecular Weight333.3574
CAS Registry Number70458-92-3;149676-40-4
Density1.32g/cm3
Boiling point529.1°C at 760 mmHg
Refractive index1.593
Flash point273.8°C
Vapour Pressur5.05E-12mmHg at 25°C


Molecular Structure


Pefloxacin is a quinolone drug used to treat bacterial infections. Pefloxacin has not been approved for use in the United States.


History

Pefloxacin was developed in 1979 and approved in France for human use in 1985.


Licensed uses

Uncomplicated gonococcal urethritis in males.

Bacterial infections in the gastrointestinal system.

Genitourinary tract infections.

Gonorrhoeae. however this indication is no longer effective due to bacterial resistance.

Pefloxacin has been increasingly used as a veterinary medicine to treat microbial infections.


Mode of action

Pefloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV, which is an enzyme necessary to separate, replicated DNA, thereby inhibiting cell division.


Adverse effects

Tendinitis and rupture, usually of the Achilles tendon, are a class-effects of the fluoroquinolones, most frequently reported with pefloxacin. The estimated risk of tendon damage during pefloxacin therapy has been estimated by the French authorities in 2000 to be 1 case per 23,130 treatment days as compared to ciprofloxacin where it has been estimated to be 1 case per 779,600.


Indications

See norfloxacin clinical indications. Intravenous administration can still be used for severe cases of lung infection, can also be used for Gram-negative bacilli sepsis, sepsis often require treatment with antimicrobials synergistic combination. For adults G- bacteria and staphylococcus severe infections such as sepsis, endocarditis, bacterial meningitis, respiratory tract, urinary tract, kidney, ENT infections, gynecological diseases, abdomen, liver and gallbladder, osteoarthritis and skin infections.


Dosage

Oral, once 0.4g, 2 times a day. The first dose may be doubled. Intravenously once 0.4g, 2 times a day. Dissolved in isotonic glucose injection. Instillation not too fast, one hour dropwise. The oral administration and are each adult intravenous dose 400mg, every 12h1 times, urinary tract infections and other mild infection dose reduce it. Every 400mg intravenous infusion of the product, the need to 250ml 5% glucose solution diluted dark slow intravenous infusion time of at least 1h, can not be diluted with saline or other chlorine solution to prevent precipitation. Ascites and jaundice, per the 2nd medication once.


Adverse reactions

Can cause gastrointestinal irritation or discomfort, heartburn, nausea, vomiting, loss of appetite. Mild nervous system response. Dizziness, somnolence, headache, tremor, anxiety. Withdrawal symptoms (normal). Allergies: rash, itching, palpitations, chest tightness, facial or skin flushing, conjunctival hyperemia. It can cause liver damage, withdrawal symptoms (normal). Can cause kidney damage, elevated blood urea nitrogen, may also have leukopenia and thrombocytopenia, increased eosinophils. There are lead joint and muscle pain reported. See norfloxacin.

Gastrointestinal reactions caused by this product than norfloxacin, ofloxacin and enoxacin is more common, more common than photosensitive dermatitis, accounting for about half of those rash. Norfloxacin adverse reactions are:

1, nausea, vomiting, abdominal discomfort, diarrhea, satisfied by other gastrointestinal reactions.

2, dizziness, headache, emotionally disturbed, the incidence of insomnia and other nervous system reactions, gastrointestinal reactions such reactions below.

3, rash, pruritus, angioedema, light dermatitis and other allergic reactions, can occur even anaphylactic shock.

4, a small number of patients may have muscle pain, weakness, joint pain, heart palpitations and so on.

5, laboratory tests may be a transient leukopenia, serum transaminases, blood urea nitrogen and creatinine of slightly elevated, it is also reversible.

These adverse reactions are mild, most patients can tolerate. However, norfloxacin and other fluoroquinolones even can cause serious adverse reactions, including:

1, altered mental status, sleeves twitch, epileptic seizures.

2, transient hallucinations, visual hallucinations, diplopia.

3, crystallization of urine, occurred in the high-dose medication.


Pefloxacin CAS 70458-92-3 149676-40-4 RB-1589 Pefloxacine Mesylate Dihydrate Pefloxacine Methansulfonate Dihydrate

Appearance: white powder

Pefloxacin CAS 70458-92-3 149676-40-4 RB-1589 Pefloxacine Mesylate Dihydrate Pefloxacine Methansulfonate Dihydrate

Package: 25KG Drum or As per request of clients

Category: Veterinary Medicine API

Related Category: Antibiotic Drugs API  Antineoplastic Drugs API  Heart And Cerebral Vessels API  Hot anti-cancer medicines  Pharmaceutical Intermediates 


«
Offline Showroom in USA
QR Code